PL3816164T3 - Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4 - Google Patents
Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4Info
- Publication number
- PL3816164T3 PL3816164T3 PL19825725.5T PL19825725T PL3816164T3 PL 3816164 T3 PL3816164 T3 PL 3816164T3 PL 19825725 T PL19825725 T PL 19825725T PL 3816164 T3 PL3816164 T3 PL 3816164T3
- Authority
- PL
- Poland
- Prior art keywords
- isothiazolo
- pyrimidine compound
- irak4 inhibitor
- irak4
- inhibitor
- Prior art date
Links
- 229940127590 IRAK4 inhibitor Drugs 0.000 title 1
- -1 Isothiazolo[5,4-d]pyrimidine compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810662580 | 2018-06-25 | ||
| CN201910463156 | 2019-05-30 | ||
| PCT/CN2019/092867 WO2020001449A1 (zh) | 2018-06-25 | 2019-06-25 | 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3816164T3 true PL3816164T3 (pl) | 2024-08-12 |
Family
ID=68986119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19825725.5T PL3816164T3 (pl) | 2018-06-25 | 2019-06-25 | Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11459337B2 (pl) |
| EP (1) | EP3816164B9 (pl) |
| JP (1) | JP7511489B2 (pl) |
| KR (1) | KR20210024543A (pl) |
| CN (2) | CN112243438B (pl) |
| AU (1) | AU2019296118B2 (pl) |
| BR (1) | BR112020026507A8 (pl) |
| CA (1) | CA3104380A1 (pl) |
| DK (1) | DK3816164T5 (pl) |
| ES (1) | ES2978674T3 (pl) |
| HU (1) | HUE066411T2 (pl) |
| PL (1) | PL3816164T3 (pl) |
| WO (1) | WO2020001449A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021147968A1 (zh) * | 2020-01-21 | 2021-07-29 | 正大天晴药业集团股份有限公司 | 一种irak4抑制剂的结晶及其制备方法 |
| WO2024217522A1 (zh) * | 2023-04-21 | 2024-10-24 | 正大天晴药业集团股份有限公司 | 一种异噻唑并[5,4-d]嘧啶类化合物治疗炎性疾病的用途 |
| CN117164479A (zh) * | 2023-08-21 | 2023-12-05 | 甘肃康巴斯生物科技有限公司 | 一种氨基乙腈盐酸盐的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012097013A1 (en) | 2011-01-10 | 2012-07-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| WO2014011906A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN106232122A (zh) * | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017186689A1 (en) | 2016-04-29 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| EP3448849B1 (en) | 2016-04-29 | 2020-05-13 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
-
2019
- 2019-06-25 ES ES19825725T patent/ES2978674T3/es active Active
- 2019-06-25 EP EP19825725.5A patent/EP3816164B9/en active Active
- 2019-06-25 CN CN201980040052.2A patent/CN112243438B/zh active Active
- 2019-06-25 PL PL19825725.5T patent/PL3816164T3/pl unknown
- 2019-06-25 BR BR112020026507A patent/BR112020026507A8/pt unknown
- 2019-06-25 HU HUE19825725A patent/HUE066411T2/hu unknown
- 2019-06-25 KR KR1020217001278A patent/KR20210024543A/ko active Pending
- 2019-06-25 US US17/254,778 patent/US11459337B2/en active Active
- 2019-06-25 DK DK19825725.5T patent/DK3816164T5/da active
- 2019-06-25 CA CA3104380A patent/CA3104380A1/en active Pending
- 2019-06-25 AU AU2019296118A patent/AU2019296118B2/en active Active
- 2019-06-25 WO PCT/CN2019/092867 patent/WO2020001449A1/zh not_active Ceased
- 2019-06-25 JP JP2020572821A patent/JP7511489B2/ja active Active
- 2019-06-25 CN CN202210418417.4A patent/CN114716455A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021529751A (ja) | 2021-11-04 |
| EP3816164A4 (en) | 2022-03-16 |
| BR112020026507A2 (pt) | 2021-03-23 |
| AU2019296118A8 (en) | 2021-01-28 |
| DK3816164T3 (da) | 2024-04-22 |
| CN112243438B (zh) | 2022-03-15 |
| KR20210024543A (ko) | 2021-03-05 |
| DK3816164T5 (da) | 2024-07-22 |
| US11459337B2 (en) | 2022-10-04 |
| EP3816164B9 (en) | 2024-07-10 |
| EP3816164A1 (en) | 2021-05-05 |
| CA3104380A1 (en) | 2020-01-02 |
| AU2019296118B2 (en) | 2024-09-26 |
| EP3816164B1 (en) | 2024-04-03 |
| AU2019296118A1 (en) | 2020-01-02 |
| HUE066411T2 (hu) | 2024-08-28 |
| BR112020026507A8 (pt) | 2023-01-31 |
| CN114716455A (zh) | 2022-07-08 |
| JP7511489B2 (ja) | 2024-07-05 |
| WO2020001449A1 (zh) | 2020-01-02 |
| ES2978674T3 (es) | 2024-09-17 |
| CN112243438A (zh) | 2021-01-19 |
| US20210269459A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276802A (en) | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidin-3-ones | |
| IL291471A (en) | Pyrimido[3,2-d]pyrimidine compounds as immunomodulators | |
| EP4037688A4 (en) | ANTIVIRAL HETEROCYCLIC COMPOUNDS | |
| SG11202104326TA (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| IL272262A (en) | Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one | |
| SG11201801365YA (en) | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | |
| DK3880676T3 (da) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-on-derivater som hpk1-inhibitorer til behandling af cancer | |
| CA3264151A1 (en) | Antiviral pyridopyrazinedione compounds | |
| IL284767A (en) | Heterocyclic compounds as adenosine antagonists | |
| IL290445A (en) | [1,2,4]triazolo[1,5-c]quinazolin-5-amines | |
| CA3275666A1 (en) | Crystalline forms of the nrtti compound 4’-ethynyl-2-fluoro-2’- deoxyadenosine | |
| IL284762A (en) | Heterocyclic compounds as adenosine antagonists | |
| HUE066411T2 (hu) | Izotiazolo[5,4-d]pirimidin vegyület mint IRAK4 inhibitor | |
| EP3858838A4 (en) | Heterocyclic compound | |
| EP3831811A4 (en) | HETEROCYCLIC COMPOUND | |
| IL274963A (en) | Thiano[2,3-d]pyrimidine compound with inhibitory activity for protein kinase | |
| IL289141A (en) | Compounds 7,8 dihydro-4h-pyrazolo[3,4-c]azepin-6-one | |
| TN2017000065A1 (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor | |
| EP3878587A4 (en) | ROUND | |
| EP3878586A4 (en) | LATHE | |
| HK40077793A (en) | Antiviral heterocyclic compounds | |
| HK40064784A (en) | Heterocyclic compounds as adenosine antagonists | |
| HK40055110A (en) | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors | |
| HK40055108A (en) | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors | |
| HK40041290A (en) | Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors |